Crinetics Pharmaceuticals Prices $350M Public Offering at Discount to Market, Securing Significant Capital
CRNX has more than doubled off its 52-week low of $24.1 on elevated volume (3.5× avg).
Summary
Crinetics Pharmaceuticals announced the pricing of a public offering to raise up to $379.8 million, with shares priced at a discount to the current market, to fund commercial activities and R&D.
Key Events · Financing and Capital Events · CRNX
-
Public Offering Priced
Crinetics Pharmaceuticals priced an underwritten public offering of 7,620,000 shares of common stock at $45.95 per share.
-
Underwriters' Option
The company granted underwriters a 30-day option to purchase up to an additional 1,143,000 shares of common stock.
-
Significant Net Proceeds
The offering is expected to generate approximately $330.2 million in net proceeds, potentially rising to $379.8 million if the option is fully exercised.
-
Use of Proceeds
Proceeds will fund commercial activities for PALSONIFY™ launch, research and development of product candidates, other research programs, and general corporate purposes.
Analysis · CRNX · Life Sciences
Crinetics Pharmaceuticals has priced a substantial public offering, raising approximately $330.2 million, potentially increasing to $379.8 million if the underwriters' option is fully exercised. This capital raise is significant for a life sciences company, providing crucial funding for the commercial launch of PALSONIFY™, ongoing research and development, and general corporate purposes. While the offering is dilutive, the successful securing of such a large sum extends the company's financial runway. The pricing of the shares at $45.95, a discount to the current market price of $53.13, indicates the concessions made to attract investors for this capital infusion.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.8% of the 1618 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRNX was trading at $53.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $24.10 to $57.99. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.